申请人:Pfizer Inc.
公开号:US05158964A1
公开(公告)日:1992-10-27
A series of novel N-alkyl N-(alkanesulphonamidoheterocyclicmethyl)-4-alkanesulphonamidophenethylamin es have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzo-fused heterocyclic group derived from either benzofuran, benzothiophene, benzoxazole or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Preferred member compounds include N-methyl-N-(5 methanesulphonamidobenzofur-2-ylmethyl)-4-methanesulphonamidophenethylamin e and N-methyl-N-(6 methanesulphonamidoquinol-2-ylmethyl)-4-methanesulphonamidophenethylamine. Methods for preparing all these compounds from known starting materials are provided.
一系列新型的N-烷基N-(烷基磺酰胺杂环甲基)-4-烷基磺酰胺苯乙胺已被制备,包括它们的药学上可接受的盐和各种关键的新型中间体。这些化合物中存在的杂环基团是从苯并呋喃、苯并噻吩、苯并噁唑或喹啉中派生出来的苯并杂环基团,并且通过可用的环碳原子与分子中毗邻的甲基基团连接,该环碳原子位于杂原子α位。这些特定的化合物在治疗中是有用的,因为它们是高效的抗心律失常药物,因此对于治疗各种心脏心律失常具有价值。首选的成员化合物包括N-甲基-N-(5-甲烷磺酰胺基苯并呋喃-2-基甲基)-4-甲烷磺酰胺苯乙胺和N-甲基-N-(6-甲烷磺酰胺基喹啉-2-基甲基)-4-甲烷磺酰胺苯乙胺。提供了从已知起始材料制备所有这些化合物的方法。